NantHealth, which has developed genomic and protein-based molecular testing services—starting with cancer care—on a personalized medicine platform, has filed SEC registration papers to conduct an initial public offering of stock valued at up to $92 million.NantHealth, which has developed genomic and protein-based molecular testing services—starting with cancer care—on a personalized medicine platform, has filed SEC registration papers to conduct an initial public offering of stock valued at up to $92 million.

The company has requested NH as its ticker symbol on the NASDAQ stock exchange. Backed by billionaire investor Patrick Soon-Shiong, M.D., NantHealth has been in development for several years, but took major steps in 2015 and early 2016 toward deploying its platform.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access